InvestSMART

Cynata Therapeutics Limited (ASX:CYP)

ALERT: Price-sensitive ASX Announcement for CYP
Current share price for CYP : $0.012 -0.311 (-96.28%)+
Announcement
Release
30 Apr 2026 10:00AM
Price at Release
$0.323
Full Release
download
Summary
Cynata Therapeutics Limited (ASX: CYP) released its March 2026 Quarterly Activity Report, highlighting a transformative period ahead with upcoming results from two major trials: a Phase 2 trial for acute graft versus host disease (aGvHD) and a Phase 3 trial for osteoarthritis. The trials are set to provide key efficacy data in June and May 2026, respectively. Cynata's cash balance at the end of the quarter was $1.6 million, and the company announced a trading halt pending a capital raising. The company's Cymerus™ platform continues to pioneer MSC-based therapies, with several ongoing clinical trials and a robust pipeline in regenerative medicine. Additionally, the company actively engaged with investors and stakeholders, strengthening its intellectual property portfolio with new patents. Cynata remains optimistic about market approval in Australia following positive trial outcomes.
Key Points
  • Cynata is expecting results from two major clinical trials in mid-2026.
  • The company ended the quarter with a cash balance of $1.6 million.
  • Cynata entered a trading halt pending a capital raising announcement.
  • The Cymerus™ platform is key to their MSC-based therapy development.
  • Cynata engaged with investors and stakeholders during the quarter.
  • New patents were added to strengthen Cynata's intellectual property portfolio.
  • Cynata is optimistic about market approval in Australia for its therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.